<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580173</url>
  </required_header>
  <id_info>
    <org_study_id>95753</org_study_id>
    <nct_id>NCT04580173</nct_id>
  </id_info>
  <brief_title>Correlation of Clinical Types and Complexity of Coronary Artery Disease With Patients' Metabolic Profile</brief_title>
  <acronym>CorLipid</acronym>
  <official_title>Correlation of Clinical Types and Complexity of Coronary Artery Disease With Patients' Metabolic Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ANALYSIS MEDICAL SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratory of Forensic Medicine and Toxicology, Medical School, Aristotle University of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research project is to investigate the potential association of the&#xD;
      complexity and the severity of coronary artery disease (as assessed via SYNTAX score) with&#xD;
      patients' metabolic profile. The aim of the study is to combine biochemical, clinical and&#xD;
      laboratory data in order to create an algorithm that will enable an individualized&#xD;
      therapeutic patient approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this observational study is to expand our knowledge on the biochemical&#xD;
      process and pathogenesis of atherogenesis and to recognize clinically important metabolic&#xD;
      biomarkers correlated with the severity and clinical presentation of Coronary Artery Disease&#xD;
      (CAD). 1050 patients who will undergo coronary angiography will be enrolled in the study.&#xD;
      SYNTAX score will be calculated for all participants and their blood samples will be&#xD;
      collected before coronary angiography. Metabolomics-based analysis will be performed in order&#xD;
      to confirm CAD prognostic biomarkers previously reported in the literature and to investigate&#xD;
      their correlations with CAD clinical data. The ultimate aim of this study is to predict the&#xD;
      risk of cardiovascular events by incorporating metabolomic information into the SYNTAX score&#xD;
      and provide personalized therapeutic guidance to patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Relationship between metabolic profile and the SYNTAX score</measure>
    <time_frame>12 months</time_frame>
    <description>Serum metabolomic biomarkers (ceramides, acyl-carnitines, total fatty acids and protein markers: Galectin-3, Neutrophil Gelatinase-Associated Lipocalin, Adiponectin, ApolipoproteinB/ ApolipoproteinΑ-Ι) will be quantified using metabolomics-based methods and enzyme-linked immunosorbent assay. The SYNTAX score will be calculated for all patients. Correlation between patients' metabolic profile and the SYNTAX score will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum ceramide species</measure>
    <time_frame>12 months</time_frame>
    <description>Quantification of serum ceramide species (C18:0/16:0, C18:0/18:0, C18:0/24:0 and C18:0/24:1) using a developed Ultra-high performance liquid chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum acyl-carnitines</measure>
    <time_frame>12 months</time_frame>
    <description>Quantification of serum acyl-carnitines (C2, C3, C4, isoC4, C5, isoC5, C6, C8, C10, C12, C14, C16, C18, C18:1 C18:2) using a developed hydrophilic interaction chromatography tandem mass spectrometry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum total fatty acids</measure>
    <time_frame>12 months</time_frame>
    <description>Quantification of total fatty acids (C10:0, C12:0, C14:0, C15:0, C16:0, C16:1, C17:0, C18:0, C18:1 cis, C18:2 cis, C20:0, C18:3 n6, C18:3 n3, C20:1, C20:2, C22:0, C20:3 n6, C22:1 &amp; C20:4, C23:0, C20:5, C24:0, C24:1, C22:6) using a developed gas chromatography with flame-ionization method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum selective protein markers</measure>
    <time_frame>12 months</time_frame>
    <description>Quantification of selective protein markers (Galectictin-3, NGAL, Adiponectin, ApoB/ ApoΑ-Ι)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular and Cerebrovascular Events</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular death, myocardial infarction, stent thrombosis, revascularization and stroke</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>SYNTAX score = 0</arm_group_label>
    <description>Patients with nonobstructive CAD (≤50 % diameter stenosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 &lt; SYNTAX score &lt;=22</arm_group_label>
    <description>Low SYNTAX group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>23&lt;=SYNTAX score&lt;=32</arm_group_label>
    <description>Intermediate SYNTAX group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYNTAX score&gt;=33</arm_group_label>
    <description>High SYNTAX group</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>metabolomics analysis</intervention_name>
    <description>Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.</description>
    <arm_group_label>0 &lt; SYNTAX score &lt;=22</arm_group_label>
    <arm_group_label>23&lt;=SYNTAX score&lt;=32</arm_group_label>
    <arm_group_label>SYNTAX score = 0</arm_group_label>
    <arm_group_label>SYNTAX score&gt;=33</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults, of both genders, who are admitted in the Department of Cardiology in the AHEPA&#xD;
        University General Hospital of Thessaloniki and undergo coronary angiography for clinical&#xD;
        purposes will be studied. Patients with a previous history of coronary artery disease will&#xD;
        be excluded. The study includes subjects who 1) have suspected CAD and undergo a scheduled&#xD;
        diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute&#xD;
        coronary syndrome and thus undergo diagnostic angiography (without previous history of&#xD;
        CAD).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients giving voluntary written consent to participate in the study&#xD;
&#xD;
          2. Adults&#xD;
&#xD;
          3. Patients without previous history of coronary artery disease&#xD;
&#xD;
          4. Patients who are admitted in the Department of Cardiology in the AHEPA University&#xD;
             General Hospital of Thessaloniki and undergo coronary angiography for clinical&#xD;
             purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac Arrest at admission&#xD;
&#xD;
          2. Patients with serious concurrent disease and life expectancy of &lt; 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Georgios Sianos, PhD</last_name>
    <phone>2310994837</phone>
    <phone_ext>0030</phone_ext>
    <email>gsianos@auth.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Sianos, MD PhD FESC</last_name>
      <phone>2310994837</phone>
      <phone_ext>0030</phone_ext>
      <email>gsianos@auth.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Sianos, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Theodoridis, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helen Gika, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Efstratios Karagiannidis, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleftherios Panteris, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Sofidis, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Deda, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Begou, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomais Mouskeftara, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Meikopoulos, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005 Aug;1(2):219-27.</citation>
    <PMID>19758907</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Georgios Sianos</investigator_full_name>
    <investigator_title>Georgios Sianos, Associate Professor of Cardiology MD, PhD, FESC, AHEPA University Hospital</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The decision to share or not individual participant data with other researchers will depend on the purpose and the scope of the proposed research</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

